Approved indications for idelalisib include relapsed chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular B-cell non-Hodgkin lymphoma.
Charles E. Libby, RPh, MS
Advertisement
Articles by Charles E. Libby, RPh, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Bacteria and Fungi in the Mouth Found to Drive Pancreatic Cancer Risk
2
FDA Approves Lurbinectedin Combination Regimen in Extensive-Stage SCLC
3
Pfizer Agrees to Lower Certain Drug Prices in US, Aligning With ‘Most-Favored Nation’ Plan
4
Metabolic Bariatric Surgery Outperforms GLP-1s in Weight Loss With Lower Long-Term Costs
5
